- Home
- CALC vs FTHM Comparison
CALC vs FTHM Comparison
Compare CALC & FTHM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CALC
- FTHM
- Stock Information
- Founded
- CALC 2011
- FTHM 2010
- Country
- CALC United States
- FTHM United States
- Employees
- CALC N/A
- FTHM N/A
- Industry
- CALC Biotechnology: Pharmaceutical Preparations
- FTHM Real Estate
- Sector
- CALC Health Care
- FTHM Finance
- Exchange
- CALC Nasdaq
- FTHM Nasdaq
- Market Cap
- CALC 22.9M
- FTHM 33.6M
- IPO Year
- CALC N/A
- FTHM 2020
- Fundamental
- Price
- CALC $1.60
- FTHM $1.35
- Analyst Decision
- CALC Strong Buy
- FTHM Buy
- Analyst Count
- CALC 3
- FTHM 1
- Target Price
- CALC $16.33
- FTHM $2.50
- AVG Volume (30 Days)
- CALC 28.9K
- FTHM 83.6K
- Earning Date
- CALC 08-11-2025
- FTHM 08-11-2025
- Dividend Yield
- CALC N/A
- FTHM N/A
- EPS Growth
- CALC N/A
- FTHM N/A
- EPS
- CALC N/A
- FTHM N/A
- Revenue
- CALC N/A
- FTHM $357,816,000.00
- Revenue This Year
- CALC N/A
- FTHM $32.40
- Revenue Next Year
- CALC N/A
- FTHM $18.04
- P/E Ratio
- CALC N/A
- FTHM N/A
- Revenue Growth
- CALC N/A
- FTHM 5.80
- 52 Week Low
- CALC $1.42
- FTHM $0.65
- 52 Week High
- CALC $5.97
- FTHM $3.37
- Technical
- Relative Strength Index (RSI)
- CALC 45.69
- FTHM 61.33
- Support Level
- CALC $1.42
- FTHM $1.24
- Resistance Level
- CALC $1.79
- FTHM $1.36
- Average True Range (ATR)
- CALC 0.15
- FTHM 0.08
- MACD
- CALC -0.01
- FTHM 0.00
- Stochastic Oscillator
- CALC 38.14
- FTHM 80.49
About CALC CalciMedica Inc.
CalciMedica Inc is a clinical-stage biopharmaceutical company focused on developing therapeutics that treat serious illnesses driven by inflammatory and immunologic processes and direct cellular damage. Its product candidates act upon calcium release-activated calcium (CRAC) channels and would constitute a new class of drugs. Its product candidate is Auxora, a potent and selective intravenous formulated small molecule CRAC channel inhibitor containing the active compound zegocractin (formerly referred to as CM4620) that, in animal models, reduced acute epithelial and/or endothelial cell injury and inflammation in organs, such as the pancreas, lungs and kidneys.
About FTHM Fathom Holdings Inc.
Fathom Holdings Inc is a national, technology-driven, real estate services platform integrating residential brokerage, mortgage, title, insurance, and Software as a Service (SaaS) offering to brokerages and agents by leveraging proprietary cloud-based software, intelliAgent. The company has three reportable segments namely Real Estate Brokerage, Mortgage and Technology. The brands of the company include Fathom Realty, Dagley Insurance, Encompass Lending, intelliAgent, LiveBy, Real Results, and Verus Title. Majority of revenue is from Real Estate segment.